Teva Short Term Debt vs Accounts Payable Analysis
TEVA Stock | USD 13.98 0.10 0.71% |
Teva Pharma financial indicator trend analysis is much more than just breaking down Teva Pharma Industries prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Teva Pharma Industries is a good investment. Please check the relationship between Teva Pharma Short Term Debt and its Accounts Payable accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Teva Pharma Industries. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real.
Short Term Debt vs Accounts Payable
Short Term Debt vs Accounts Payable Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Teva Pharma Industries Short Term Debt account and Accounts Payable. At this time, the significance of the direction appears to have weak contrarian relationship.
The correlation between Teva Pharma's Short Term Debt and Accounts Payable is -0.08. Overlapping area represents the amount of variation of Short Term Debt that can explain the historical movement of Accounts Payable in the same time period over historical financial statements of Teva Pharma Industries, assuming nothing else is changed. The correlation between historical values of Teva Pharma's Short Term Debt and Accounts Payable is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Short Term Debt of Teva Pharma Industries are associated (or correlated) with its Accounts Payable. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Accounts Payable has no effect on the direction of Short Term Debt i.e., Teva Pharma's Short Term Debt and Accounts Payable go up and down completely randomly.
Correlation Coefficient | -0.08 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Short Term Debt
Accounts Payable
An accounting item on the balance sheet that represents Teva Pharma obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Teva Pharma Industries are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.Most indicators from Teva Pharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Teva Pharma Industries current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Teva Pharma Industries. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. At present, Teva Pharma's Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value is expected to grow to about 40.5 B, whereas Tax Provision is forecasted to decline to (7.3 M).
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 7.6B | 7.0B | 7.6B | 4.8B | Total Revenue | 15.9B | 14.9B | 15.8B | 9.5B |
Teva Pharma fundamental ratios Correlations
Click cells to compare fundamentals
Teva Pharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Teva Pharma fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 57.5B | 50.6B | 47.7B | 44.0B | 43.5B | 26.4B | |
Short Long Term Debt Total | 27.3B | 26.4B | 23.5B | 21.6B | 20.2B | 21.2B | |
Other Current Liab | 890M | 931M | 903M | 6.0B | 1.1B | 1.6B | |
Total Current Liabilities | 13.7B | 13.2B | 11.0B | 11.5B | 12.2B | 6.5B | |
Total Stockholder Equity | 14.0B | 10.0B | 10.3B | 7.9B | 7.5B | 9.9B | |
Property Plant And Equipment Net | 7.0B | 6.9B | 6.5B | 6.2B | 6.1B | 3.2B | |
Net Debt | 25.4B | 24.2B | 21.3B | 18.8B | 16.9B | 17.8B | |
Retained Earnings | (7.0B) | (10.9B) | (10.5B) | (12.9B) | (13.5B) | (12.9B) | |
Cash | 2.0B | 2.2B | 2.2B | 2.8B | 3.2B | 3.4B | |
Non Current Assets Total | 44.0B | 37.6B | 35.1B | 32.0B | 31.0B | 18.7B | |
Non Currrent Assets Other | 591M | 538M | 515M | 441M | 462M | 594.6M | |
Cash And Short Term Investments | 2.0B | 2.2B | 2.2B | 2.8B | 3.2B | 3.4B | |
Net Receivables | 5.7B | 4.6B | 4.5B | 3.7B | 3.4B | 3.0B | |
Common Stock Shares Outstanding | 1.1B | 1.1B | 1.1B | 1.1B | 1.1B | 777.0M | |
Liabilities And Stockholders Equity | 57.5B | 50.6B | 47.7B | 44.0B | 43.5B | 26.4B | |
Non Current Liabilities Total | 28.7B | 26.4B | 25.4B | 23.8B | 23.1B | 24.3B | |
Inventory | 4.4B | 4.4B | 3.8B | 3.8B | 4.0B | 2.4B | |
Other Current Assets | 434M | 710M | 967M | 549M | 505M | 914.4M | |
Other Stockholder Equity | 23.2B | 23.3B | 23.4B | 23.6B | 23.7B | 24.9B | |
Total Liab | 42.4B | 39.6B | 36.4B | 35.3B | 35.4B | 37.1B | |
Total Current Assets | 13.5B | 13.0B | 12.6B | 12.1B | 12.5B | 7.7B | |
Short Term Debt | 2.3B | 3.2B | 1.4B | 2.1B | 1.7B | 1.3B | |
Intangible Assets | 11.2B | 8.9B | 7.5B | 6.3B | 5.4B | 4.7B | |
Accounts Payable | 1.7B | 1.8B | 1.7B | 1.9B | 2.6B | 2.1B | |
Accumulated Other Comprehensive Income | (2.3B) | (2.4B) | (2.7B) | (2.8B) | (2.7B) | (2.6B) | |
Other Liab | 3.7B | 3.2B | 3.4B | 4.4B | 5.1B | 5.3B | |
Other Assets | 2.1B | 1.1B | 1M | (1M) | 1.9B | 950K | |
Long Term Debt | 24.6B | 22.7B | 21.6B | 19.1B | 18.2B | 12.5B | |
Property Plant Equipment | 6.4B | 6.3B | 6.0B | 6.2B | 7.1B | 4.8B | |
Current Deferred Revenue | 8.7B | 7.3B | 7.0B | 1.5B | 6.9B | 7.3B | |
Good Will | 24.8B | 20.6B | 20.0B | 17.6B | 17.2B | 17.7B | |
Property Plant And Equipment Gross | 6.4B | 6.9B | 6.5B | 6.2B | 11.8B | 12.4B | |
Short Long Term Debt | 2.3B | 3.2B | 1.4B | 2.1B | 1.7B | 2.6B | |
Net Tangible Assets | (22.1B) | (19.5B) | (17.2B) | (16.0B) | (14.4B) | (15.1B) |
Currently Active Assets on Macroaxis
When determining whether Teva Pharma Industries offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Teva Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Teva Pharma Industries Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Teva Pharma Industries Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Teva Pharma Industries. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Complementary Tools for Teva Stock analysis
When running Teva Pharma's price analysis, check to measure Teva Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Teva Pharma is operating at the current time. Most of Teva Pharma's value examination focuses on studying past and present price action to predict the probability of Teva Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Teva Pharma's price. Additionally, you may evaluate how the addition of Teva Pharma to your portfolios can decrease your overall portfolio volatility.
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Transaction History View history of all your transactions and understand their impact on performance | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |
Is Teva Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Teva Pharma. If investors know Teva will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Teva Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.4 | Earnings Share (0.50) | Revenue Per Share 14.161 | Quarterly Revenue Growth 0.148 | Return On Assets 0.0454 |
The market value of Teva Pharma Industries is measured differently than its book value, which is the value of Teva that is recorded on the company's balance sheet. Investors also form their own opinion of Teva Pharma's value that differs from its market value or its book value, called intrinsic value, which is Teva Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Teva Pharma's market value can be influenced by many factors that don't directly affect Teva Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Teva Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Teva Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Teva Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.